Myriad: A Tempest in the Biotechnology Industry Teapot?

by Wilson Sonsini Goodrich & Rosati

The U.S. Supreme Court in Association for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398 (June 13, 2013), decided that "isolated" genomic DNA is a product of nature and not patent eligible merely because it has been "isolated."1 The Court also held that claims to synthetic DNA (e.g., complementary DNA or cDNA) were valid.2 Although given broad coverage by the general media,3 Myriad may turn out to be of limited consequence to the biotechnology industry.

Myriad Genetics, Inc., a Utah-based biotechnology company, markets a genetic test that identifies when a patient carries certain mutation(s) in the BRCA1 and/or BRCA2 genes. BRCA1 and BRCA2 mutations significantly increase the risk, relative to the general population, of a patient developing cancers of the breast and ovary. Myriad's tests are protected by a variety of patent claims, including claims at issue that cover the isolated BRCA genes. The patent subject matter eligibility of only nine claims, taken from only three of Myriad's patents, was at issue before the Court.

The Court held that claims to isolated genomic DNA were not patent eligible merely because genomic DNA was isolated, but that claims to synthetic DNA were valid.4 The Court emphasized that the Myriad holding was limited in scope. For example, the Court stated that it is "important to note what is not implicated by this decision. First, there are no method claims before this Court. Had Myriad created an innovative method of manipulating genes . . . it could possibly have sought a method patent."5 "Similarly, this case does not involve patents on new applications of knowledge about the BRCA1 and BRCA2 genes."6 Indeed, the Court noted that "Many of [Myriad's] unchallenged claims are limited to such applications."7

The limited holding of Myriad is unlikely to affect many routine biotechnology patent claims. In addition to method claims,8 claims drawn to unnatural (e.g., modified) proteins and the polynucleotides that code for these, vectors (e.g., plasmids) containing isolated genes, genetically modified organisms, and methods of making and using these, all staples of the biotechnology industry, remain patent eligible post Myriad.

Proponents of the importance of Myriad's holding point to the fact that, post Myriad, other biotechnology companies are coming out with, or plan to come out with, competing BRCA testing methods.

Whether these companies will infringe Myriad's remaining, valid claims remains an open question. It is possible that since many of Myriad's original BRCA patents will expire in the next few years, and getting an injunction in this short time period may be problematic, competitors may feel emboldened. More broadly, because of the timelines associated with gene patenting, many (or most) patents that contain claims to isolated genomic DNA, had these claims remained valid, would nevertheless be expiring over the next few years, since the genome was completed almost 20 years ago. Thus, the narrow holding of Myriad, coupled with ageing patents, means that the impact of Myriad on the biotechnology industry will likely be limited.

Of some interest, it remains to be determined whether Myriad may affect other isolated natural products (e.g., statins, or antibiotics that may otherwise occur in nature). Myriad may raise issues regarding the validity of claims to these isolated natural products, and it is reasonable to predict a Myriad-based challenge at some future point. However, isolated natural products, unlike isolated genomic DNA, often contain structural features or formulations that convey biological functionality. Also, isolated natural products can have significantly different properties than the natural product in its in vivo milieu. Finally, isolated natural products are typically administered as compositions. To this end, the Court noted that "Myriad's claims are simply not expressed in terms of a chemical composition, nor do they rely in any way on chemical changes that result from the isolation of a particular section of DNA."9 Thus, it is far from clear that any Myriad-based challenge to claims drawn to isolated natural products, and compositions containing these, would be successful.

While the impact of Myriad may be limited, the case certainly increases the need for careful claim preparation.

1 Myriad at page 18.

2 Myriad at page 17.

3 Part of the media attention came from the way the issue was presented to the Court (namely, are human genes patentable?). Additional media attention came in the form of public announcements from celebrities. For example, actress Angelina Jolie recently announced she had undergone a preventative double mastectomy after learning, through genetic testing, that she carries a mutation of the BRCA1 gene, which sharply increases her risk of developing breast cancer and ovarian cancer.

4 Myriad at pages 17-18.

5 Myriad at pages 17.

6 Myriad at pages 17.

7 Myriad at pages 17-18 (citation omitted).

8 Diagnostic method claims must, however, still surmount the heightened requirements for patent eligibility set forth in Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012).

9 Myriad at page 14.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Wilson Sonsini Goodrich & Rosati | Attorney Advertising

Written by:

Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.